艾比玛特医药科技(上海)有限公司

Abmart is a Shanghai-based biotechnology and pharmaceutical company founded in 2007. It specializes in antibody customization and related services, aiming to empower scientists with the future of antibody innovation and discovery. The company excels in leveraging advanced technology and products to develop antibodies, study protein complexes, discover new targets, identify markers, and manufacture antibody drugs on a large scale. Their Series B investment of CNY20.00M on 12 June 2018 saw participation from prominent investors including Share Capital, 朗盛投资, Puming Dianli Xitong Gongcheng, Unity Asset Management, and Parkland Group. Abmart's goal is to reshape the industry and provide scientists with complementary antibodies, making it a promising player in the biotech and pharmaceutical sectors.